Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.21
$0.12
▼
$3.00
N/AN/A5,049 shs9 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+10.1%		$0.01
$0.00
▼
$0.23
N/AN/A65,007 shs300 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
XOMA Co. stock logo
XOMAP
XOMA
$24.98
$25.23
$24.93
▼
$30.00
N/AN/A2,224 shsN/A
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%+0.07%-11.76%-29.40%-90.62%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%-26.84%-15.76%-24.46%-57.62%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
XOMA Co. stock logo
XOMAP
XOMA
0.00%0.00%+0.04%-1.03%-3.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.15
$0.21
$0.12
▼
$3.00
N/AN/A5,049 shs9 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.02
+10.1%		$0.01
$0.00
▼
$0.23
N/AN/A65,007 shs300 shs
Aravive, Inc stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
▼
$2.46
N/AN/AN/AN/A
XOMA Co. stock logo
XOMAP
XOMA
$24.98
$25.23
$24.93
▼
$30.00
N/AN/A2,224 shsN/A
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
0.00%+0.07%-11.76%-29.40%-90.62%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%-26.84%-15.76%-24.46%-57.62%
Aravive, Inc stock logo
ARAV
Aravive
0.00%0.00%0.00%0.00%0.00%
XOMA Co. stock logo
XOMAP
XOMA
0.00%0.00%+0.04%-1.03%-3.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
0.00
N/AN/AN/A
XOMA Co. stock logo
XOMAP
XOMA
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$559.42MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
$8.50MN/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMAP
XOMA
$7.65MN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/A8/19/2026 (Estimated)
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/A9/24/2026 (Estimated)
Aravive, Inc stock logo
ARAV
Aravive
N/A-$0.90N/AN/AN/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMAP
XOMA
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest XOMAP, ALVOW, APLMW, and ARAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2026N/A
Alvotech stock logo
ALVOW
Alvotech
-$0.0526N/AN/AN/A$103.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
Aravive, Inc stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMAP
XOMA
$2.168.65%N/AN/AN/A

Latest XOMAP, ALVOW, APLMW, and ARAV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/11/2026
XOMA Co. stock logo
XOMAP
XOMA
quarterly$0.53918.64%7/2/20267/2/20267/14/2026
(Data available from 1/1/2013 forward)

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
35.80%
XOMA Co. stock logo
XOMAP
XOMA
N/A

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
Aravive, Inc stock logo
ARAV
Aravive
60.40%
XOMA Co. stock logo
XOMAP
XOMA
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
4N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
59N/AN/ANot Optionable
Aravive, Inc stock logo
ARAV
Aravive
20N/AN/ANo Data
XOMA Co. stock logo
XOMAP
XOMA
10N/AN/ANot Optionable

Recent News About These Companies

XOMA (XOMAP) to Announce Earnings on Thursday
July 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30928728
XOMA Royalty Corp.
May 26, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/xoma-xoma-royalty-corp/vitals
Xoma AB Series B
May 25, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/xom.b?countrycode=se
XOMA royalty (XOMA) price target decreased by 32.32% to 45.39
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/xoma-royalty-xoma-price-target-decreased-by-3232-to-4539/ar-AA23b0n2
HC Wainwright & Co. downgrades XOMA Royalty (XOMA)
April 30, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/hc-wainwright-co-downgrades-xoma-royalty-xoma/ar-AA227UKQ
LGND: XOMA Buy Adds 100+ Assets
April 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/lgnd-xoma-buy-adds-100-093600069.html
Ligand to buy XOMA Royalty for $39/share
April 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/mergers-and-acquisitions/ligand-to-buy-xoma-royalty-for-39-share/ar-AA21OScN
We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability
March 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/believe-xoma-royaltys-nasdaq-xoma-105131783.html
XOMA Royalty Hits Inflection Point as Portfolio Receipts Surpass $50 Million
March 20, 2026  |  news.themarketisopen.comN
XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
March 18, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/67977128-xoma-royalty-corporation-xoma-royalty-reports-2025-financial-results-and-highlights-recent-business-achievements-399.htm
XOMA shares climb after Q4 results top forecasts on strong royalty income
March 18, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/xoma-shares-climb-after-q4-results-top-forecasts-on-strong-royalty-income/ar-AA1YUfEs
XOMAP XOMA Royalty Corporation 8.625% CUM PERP PFD SER A
March 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/XOMAP/dividends/history
Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout
February 10, 2026  |  bizjournals.comhttps://www.bizjournals.com/boston/news/2026/02/10/generation-bio-binney-st.html
Xoma to acquire Generation Bio for $4.2913 per share
December 16, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/xoma-to-acquire-generation-bio-for-42913-per-share/ar-AA1SpIWZ
XOMA to buy struggling Generation Bio
December 16, 2025  |  thepharmaletter.comT
‘Zombie’ biotech buyer Xoma to acquire Generation Bio
December 16, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/zombie-biotech-buyer-xoma-acquire-080300783.html
Xoma acquires another struggling biotech, this time zeroing in on Generation Bio
December 16, 2025  |  fiercebiotech.comF
Lucid Capital Markets initiates coverage of XOMA Royalty Corporation - preferred stock (XOMAP) with buy recommendation
December 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/lucid-capital-markets-initiates-coverage-of-xoma-royalty-corporation-preferred-stock-xomap-with-buy-recommendation/ar-AA1S7dSc
XOMA Royalty Corporation: XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
November 21, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-11/67046282-xoma-royalty-corporation-xoma-royalty-announces-closing-of-transactions-to-acquire-lava-therapeutics-n-v-399.htm
Earnings Beat: XOMA Royalty Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
November 15, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/earnings-beat-xoma-royalty-corporation-124136880.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.15 0.00 (0.00%)
As of 07/31/2026

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.02 +0.00 (+10.07%)
As of 09:30 AM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

Aravive stock logo

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 07/31/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

XOMA stock logo

XOMA NASDAQ:XOMAP

$24.98 0.00 (0.00%)
As of 07/31/2026

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas